معرفی
Helen Philippou is a Professor at the University of Leeds, affiliated with the School of Medicine and the Division of Cardiovascular and Diabetes Research. Her work focuses on advancing safer antithrombotic therapies and understanding coagulation mechanisms.
- Qualifications: BSc (Hons) in Biomedical Sciences, PhD in Development of Activation Markers of Blood Coagulation.
Research Interests: Helen leads studies on thrombosis, aiming to develop orally administered antithrombotic drugs with reduced bleeding risks. Her group investigates:
- Protein-protein interactions in coagulation pathways.
- Clot formation and stability in vitro and in vivo.
- Enhancing fibrinolytic therapy for improved clot lysis.
- Preventing trauma-associated bleeding complications.
Academic Leadership: As Principal Investigator and Founding Director of Lunac Therapeutics Limited, she bridges academic research with commercialization. She supervises 3 PhD students directly and co-supervises 4 more, fostering global postgraduate research opportunities.
Grants and Projects: Notable funding includes a £3m Wellcome Trust Seeding Drug Discovery Initiative (2015-2017) for her work on novel anticoagulants.
Professional Engagement: Helen serves as Scientific Secretary of the British Society of Thrombosis and Haemostasis and Co-Chair of the Factor XI and Contact System SSC at the International Society of Thrombosis and Haemostasis (ISTH).
Institutional Affiliations: She is associated with the Leeds Institute of Cardiovascular and Metabolic Medicine, British Heart Foundation, and Multidisciplinary Cardiovascular Research Centre, contributing to translational science and cardiovascular research.
